Home > Reports > Global Statistics Representing Capecitabine Market Scenario by Application, Drug Formulation, Regional Outlook-Forecast

Capecitabine Market

Capecitabine Market: Information by Application (Colon Cancer, Rectal Cancer, Breast Cancer, Others) Drug Formulation (Tablets, Capsules) and Regional Outlook-Forecast Till 2031

Published On : 07 Jun, 2019
Updated On : 05 Dec, 2022
Table of Content Download Sample

Market Snapshot

Base Year:
Study Period:
Fastest Growing Market:
Largest Market:

Global Statistics Representing Capecitabine Market Scenario

Capecitabine is a chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Cancer is the second leading cause of death worldwide–around 9.6 million deaths every year are caused by cancer, WHO. In addition, more than 70% of deaths occur in low and middle-income countries. Thereon, with the increasing prevalence of cancer incidences worldwide, the overall demand for chemotherapeutic agents has increased significantly. Capecitabine has huge potential to meet the increasing need for new agents, which can more aggressively treat breast cancer in the earlier stages.

Global capecitabine market accounted for around USD 1,652 million in 2017 and is expected to grow at a healthy CAGR during the forecast period, 2023–2031.

Get more information on this report Download Sample Report

Intended Audience

  • Capecitabine Manufacturers
  • Raw Material Suppliers
  • Capecitabine Reselling Companies
  • Potential Investors
  • Research and Development Institutes
  • Traders, Distributors, and Suppliers of Capecitabine

Segmental Insights

Global capecitabine market is segmented by application and drug formulation.

By application, the market is segmented into colon cancer, rectal cancer, breast cancer, gastric cancer, and others.

By drug formulation, capecitabine market is segmented into tablets and capsules. Tablets segment is expected to dominate due to high production by manufacturers

Regional Insights

Geographically, the global capecitabine market is segmented into four regions: the Americas, Europe, Asia Pacific, and the Middle East & Africa (MEA).

The Americas is projected to dominate the global capecitabine market due to increasing prevalence of cancer in the region. Around 1,735,350 new cases of cancer were reported in 2018, National Cancer Institute. In line with this, many players are engaged in developing better treatment options. For instance, Puma Biotechnology has received positive results from the company’s lead drug Neratinib used in breast cancer. The treatment involves combination therapy with capecitabine.

Europe is the second largest market globally. This can be attributed to rising incidences of cancers, which is the second leading cause of death and morbidity in Europe. Around 3.7 million new cases occur each year in Europe, WHO. Novel therapies are the need of the hour in the region. Around USD 1.5 billion has been invested by the European government on cancer research, European Commission.

Asia Pacific is expected to witness significant growth. The region houses huge tobacco consuming population, killing more than 2.3 million every year. However, lack of awareness in the region is leading to delay in the detection of cancer. In 2018, most of the new cancer cases were diagnosed from Eastern Asia around 5.6 million, according to Cancer Organization. To educate people about symptoms and diagnosis of cancer, governments are conducting many programs and screening drives.

MEA is expected to witness steady growth as a result of growing burden of cancer on the Middle East & Africa region due to poor healthcare facilities.

Get more information on this report Download Sample Report

Key Players

  • Fresenius SE & Co. KGaA (Germany)
  • Genentech, Inc. (U.S.)
  • Dr Reddy Laboratories Ltd. (India)
  • Cipla Inc. (India)
  • Accord Healthcare Ltd. (U.K.)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Teva Pharma B.V., Sandoz Inc. (U.S.)
  • Zentiva N.V. (Netherlands)
  • Ranbaxy Laboratories Ltd. (India)
  • Capecitabine Market Segmentation

    By Application

  • Colon Cancer
  • Rectal Cancer
  • Breast Cancer
  • Gastric Cancer
  • Others
  • By Drug Formulation

  • Tablets
  • Capsules
  • Regions Covered

    • America
      • North America
        • U.S.
        • Canada
        • Mexico
      • South America
    • Europe
      • Western Europe
        • Germany
        • France
        • UK
        • Italy
        • Spain
        • Rest of Western Europe
      • Eastern Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • South Korea
      • Australia
      • Rest of Asia Pacific
    • The Middle East & Africa
      • The Middle East
        • Saudi Arabia
        • UAE
        • Qatar
        • Rest of the Middle East
      • Africa

    Why Buy This Report?

    • Historical inferences, findings & analysis of the market from 2016 to 2018
    • Projections and performance forecast analysis for the future from 2019 to 2026
    • Production and consumption point of view (POV) analysis
    • Market drivers, restraint and opportunity analysis, to define market dynamics covering industry, regulatory, innovation, technological & pricing trends
    • Comprehensive competitive landscape mapping with recent development covering market leadership, competency, sustainability, and prospects
Report Metric Details
Market Size USD in Billion By 2030
Historical Data 2019-2020
Base Year 2021
Forecast Period 2022-2030
Forecast Units Value (USD Million)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Segments Covered by Application (Colon Cancer, Rectal Cancer, Breast Cancer, Others) Drug Formulation (Tablets, Capsules)
Geographies Covered North America, Europe, Asia-Pacific, LAME and Rest of the World
Key Companies Profiled/Vendors Fresenius SE & Co. KGaA (Germany), Genentech, Inc. (U.S.), Dr Reddy Laboratories Ltd. (India), Cipla Inc. (India), Accord Healthcare Ltd. (U.K.), F. Hoffmann-La Roche Ltd. (Switzerland), Teva Pharma B.V., Sandoz Inc. (U.S.), Zentiva N.V. (Netherlands), and Ranbaxy Laboratories Ltd. (India).
Key Market Opportunities The Healthcare It Industry'S Substantial Growth Fuels The Capecitabine Market
Price Starts From

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

As featured on :

Trusted by Fortune 500
Over 30000+ subscribers